CMS has released its interim results for the first half of 2026, showing steady growth across key financial metrics. Revenue climbed 12.5% year-on-year to approximately RMB 4.5 billion, while gross profit rose 11.4% to around RMB 3.221 billion. Profit for the period increased 4.3% to RMB 971.5 million, with profit attributable to shareholders of the company up 4.77% to RMB 986 million. Basic earnings per share stood at RMB 0.4075, and an interim dividend of RMB 0.1634 per share was declared.
The first half of 2026 underscored the tangible progress of CMS's growth engine transition. Revenue from products affected by national centralized procurement (VBP) largely stabilized, while innovative drugs and exclusive products emerged as key growth drivers, fueling robust increases in both revenue and period profit. Combined revenue from innovative and exclusive products reached RMB 1.6987 billion, up 19.7% year-on-year and accounting for 37.7% of total revenue, compared to RMB 1.419 billion and 35.5% in the prior-year period. Excluding other sources, total pharmaceutical sales revenue from these products hit approximately RMB 1.709 billion, a 20.5% increase, with their revenue share expanding to 32.0% from 30.4% previously.
The company's innovation pipeline continues to deliver results. Three innovative drugs received market approval during the period, while five innovative drugs (covering six indications) are under regulatory review for New Drug Applications. Additionally, three self-developed products (covering five indications) obtained approval for Investigational New Drug applications, and one new collaboration was added. The partnership involves an innovative intravenous iron product already marketed in China and one original intravenous iron product. CMS continues to advance its innovative pipeline and product portfolio as planned.
Furthermore, the group's specialty segment strengths have been further consolidated, with ongoing progress in product registration and commercialization validation as part of its international expansion strategy. These developments lay a more solid foundation for high-quality, sustainable growth moving forward.